M ANY YEARS HAVE PASSED SINCE THE DIS COV ERY OF PENI CIL -
lin by Fleming in 1929 and, al though many other an timi cro bi als have since been dis cov ered, the de bate re gard ing op ti mal doses and dos ing regi mens con tin ues. An ti mi cro bial ther apy is unique in many re spects since the 'r ece ptors' to which the anti-microbial is di rected is a liv ing mi cro or gan ism that may be found in vir tu ally any lo ca tion in the body. The deter mi nants of out come of the in fec tious pro cess have been well de scribed and in clude a com plex in ter ac tion among the mi cro or gan ism (bug), the an ti mi cro bial (drug) and the infected in di vid ual (host). The bug-drug-host in ter ac tion may be de scribed in terms of the phar ma coki net ics of the drug, pharma co dy nam ics of the bug-drug in ter ac tion and the host response. Phar ma coki net ics deals with the dis po si tion of the drug in the body and the pro vi sion of ac tive drug at the site of the in fec tion, whereas phar ma co dy nam ics deals with the time course of drug ac tiv ity and the mecha nisms of ac tion of drugs on the mi cro or gan ism. The host re sponse is proba bly the most im por tant vari able in any bug-drug-host in ter ac tion since it is the abil ity of the host to de stroy or con tain the mi croor gan isms that ul ti mately leads to re cov ery.
It is the in ter play of drug phar ma coki net ics, pharmaco dynam ics and the host re sponse on which dos ing regi mens of an ti mi cro bi als are pro posed. The con cept of a thera peu tic level with re spect to peni cil lin was dis cussed as early as 1944 (1) . It was sug gested that con tinu ous ther apy with peni cil lin was neces sary to main tain a criti cal level dur ing ther apy. Stud ies conducted in the early 1950s us ing a mouse model dem on strated that in ter mit tent ther apy was as ef fec tive as con tinu ous therapy (2,3). The suc cess in these early tri als with in ter mit tent dos ing was thought to de pend on the length of the dos age inter val and the amount of time dur ing which drug lev els remained ef fec tive in the se rum. Based on these early stud ies most an ti mi cro bi als have been given as in ter mit tent doses with usual dos age sched ules of three or four times daily. With beta-lactam agents it was also thought that some bac te rial regrowth was nec es sary to ob tain bac te ri cidal ac tiv ity.
Dur ing the past dec ade fac tors gov ern ing the phar ma cokinetic pa rame ters of an ti mi cro bi als (dis tri bu tion into tis sues, free ver sus bound an ti mi cro bi als, ef fect of dos age on half-life) have been fur ther clari fied and at ten tion has shifted to wards new phar ma co dy namic pa rame ters other than the tra di tional in vi tro and static mini mal in hibi tory con cen tra tion (MIC). New data have ac cu mu lated on the dy namic in ter ac tion of the bug-drug in ter ac tion, in clud ing the rate of bac te rial kill ing, the postan ti bi otic ef fect (PAE), the in flu ence of sub in hibi tory drug con cen tra tions, ef fec tive re growth time and postan ti bi otic leuko cyte en hance ment (4). The phar ma co dy namic ac tiv ity of a spe cific an ti mi cro bial may vary con sid era bly de pend ing on the mi cro or gan ism and the set ting in which it is used. The differ ent phar ma co dy namic pa rame ters among classes not unex pect edly will have a ma jor im pact on the de ter mi nants of op ti mal dos ing regi mens. As in for ma tion has ac cu mu lated from in vi tro ki netic mod els, ani mal mod els and, to a lesser extent, hu man clini cal tri als, the tra di tional ap proaches to an timi cro bial dos ing are be ing ques tioned, and al ter na tive dos ing regi mens are be ing pro posed and im ple mented in many Cana dian hos pi tals.
For ex am ple, both in vi tro mod els and ani mal stud ies have dem on strated that the most re li able pre dic tor of in vi tro ac tivity for beta-lactams is the time dur ing which the an ti mi cro bial se rum con cen tra tion ex ceeds the MIC of the of fend ing pathogen (5-11). The very high ini tial se rum con cen tra tions obtained af ter par enteral ad mini stra tion do not ap pear to con trib ute to the ef fi cacy of these agents. The bac te ri cidal activ ity of the peni cil lins and cepha lo sporins does not in crease with in creas ing se rum con cen tra tions, pro vided the MICs of the mi cro or gan ism are ex ceeded. The PAE (sup pres sion of bac te rial growth that per sists af ter brief ex po sure of or ganisms to an ti mi cro bi als) for beta-lactams has been ob served since the ini tial dis cov ery of an ti mi cro bi als (12) . Most betalactams have in vi tro PAEs of 1.5 to 3 h against most Grampositive mi cro or gan isms but rela tively short or no PAE (less than 0.5 h) against Gram-negative mi cro or gan isms (4). The car bape nems (imipe nem) are an ex cep tion to this gen eral rule for Gram-negatives, ex hib it ing a PAE of more than 1 h (4). Fur ther more, it must be em pha sized that in vivo PAEs are more pro longed than in vi tro PAEs (13) , likely due to the presence of neu tro phils and se rum fac tors (14) . Since the time dur ing which drug con cen tra tions ex ceed the MIC ap pears to be a ma jor de ter mi nant of ef fi cacy of beta-lactams, con tinuous in fu sion of agents with very short half-lives but mod est an ti bac te rial ac tiv ity or in ter mit tent in fu sion of agents with longer half-lives but with very high an ti bac te rial ac tiv ity may be the pre ferred routes of de liv ery. An other im por tant ob serva tion is that, with the ex cep tion of en do car di tis and per haps men in gi tis, no ad di tional bene fits are seen with ex tremely high con cen tra tions of beta-lactams. The rele vant im pact of these find ings to the prac tis ing cli ni cian is that the large mul tigram dos ages of the newer ex tended spec trum peni cil lins and the sec ond-and third-generation cepha lo sporins commonly used dur ing the 1980s are no longer gen er ally nec essary. Spe cific ex am ples in clude the use of piper acil lin every 6 to 8 h, cef tri ax one 1 to 2 g every 24 h, ce fo taxime 1 to 2 g every 12 h and cef tazidime 1 to 2 g every 12 h (15-20) . These dos ing regi mens take ad van tage of the ex cel lent an ti bac te rial ac tiv ity (ex tremely low MICs) and ex tended half-lives of the par ent com pound or of an ac tive me tabo lite as in the case of ce fo taxime.
The ami no gly cosides, qui nolones and met roni da zole are ex am ples of an ti mi cro bi als that ex hibit ma jor concentrationdependent kill ing and that pro duce pro longed PAEs. These agents have a kill rate that is great est at high con cen tra tions (4, 21) . Sev eral ani mal mod els and clini cal data have cor related peak ami no gly co side se rum con cen tra tions with outcome (22) (23) (24) (25) (26) . It has been sug gested that peak lev els eight-to 10-fold higher than the MIC are ca pa ble of pre vent ing any regrowth of re sis tant or gan isms (27) . The in vi tro PAEs for amino gly cosides against most Gram-positive and Gram-negative or gan isms are at least 2 to 3 h, and the in vivo PAEs have been re corded to be as high as 12 h (13). Simi larly, qui nolones have in vi tro PAEs from 1.5 to 3 h for Gram-negative ba cilli, whereas met roni da zole has a pro longed PAE (greater than 3 h) ver sus an aero bic bac te ria (4). The rele vant im pact for the cli ni cian has been the ad vent of once-daily dos ing of ami nogly cosides at a dose of 5 to 7 mg/kg (28, 29) for gen ta mi cin and to bra my cin and twice-daily dos ing of met roni da zole in con ven tional doses, which has been adopted by many hos pitals.
In the fu ture, it is likely that fur ther re fine ments to an ti micro bial dos ing will oc cur not only for spe cific agents but also for spe cific pa tient popu la tions. Tri als are un der way with continu ous low dose in fu sions of beta-lactams, and the first large ran dom ized pro spec tive trial of once-ver sus multiple-daily ami no gly co side dos ing in feb rile neu tro penic pa tients has been com pleted (30) . Not only are we likely to see fur ther new de vel op ments in the dos ing and de liv ery of es tab lished an timi cro bi als, but char ac teri za tion of the op ti mal dos ing pa rameters for newer agents will likely also oc cur dur ing their pre mar ket ing evalua tion. We hope that all of these de vel opments will con tinue to move to wards im proved clini cal outcomes and re duced tox ic ity in the pa tient popu la tions that we serve.
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